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Pertussis (whooping cough) is an infectious disease caused by Bordetella pertussis,
which primarily affects infants and young children . The infection results in a severe
paroxysmal cough persisting for weeks and can cause death when acquired within
the first year of life. The cellular vaccine introduced in the forties drastically reduced
morbidity and mortalitydue to whooping cough . The efficacy of the vaccine, com-
posed of inactivated whole cells ofB . pertussis, usually administered with diphtheria
and tetanus toxoids adsorbed with alum, is considered to be rather high (1, 2) . As
a consequence of the disappearance of pertussis in many countries after extensive
vaccination campaigns, public fears about adverse reactions to vaccination have grown .
Indeed, these reactions can rangefrom frequent feverand local tenderness, to severe
neurological complications and death . Thus, the use of the vaccine has decreased
in several countries including Sweden, England, and Japan, with a resulting increase
in infant mortality from the disease (3) . It is therefore evident that there is an urgent
need for a new, safer and effective vaccine . Indeed, a new acellular vaccine, which
includes soluble pertussis toxin (PT)' and filamentous hemagglutinin (FHA), has
been introduced in Japan, but the first controlled field trial performed in Sweden
is providing controversial results (4) . Again, this new generation of pertussis vac-
cines will be the result of an empirical approach . In fact, very little is as yet known
about the host immune response to B. pertussis . This makes the rational design of
effective new vaccines very difficult, even though recombinant proteins from B. per-
tussis are now available (5-8) .
The aim of this study was to investigate humoral and cellular responses in adults
who had suffered from pertussis in childhood . On the basis of the high degree of
protection in previously infected people, these studies were expected to help to define
the minimal antigenic structures that may be worthy of consideration for introduc-
tion into a third generation recombinant or synthetic vaccine .
Materials and Methods
Donors .
￿
PBMC and sera were collected from 52 healthy donors (aged 30-45 yr) with nega-
tive or positive anamnesis for whooping cough in childhood, but never vaccinated against
B. pertussis .
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1 Abbreviations used in this paper . FHA, filamentous hemagglutinin; PT, pertussis toxin .
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ELISA Against PT .
￿
Sera were stored at -80'C to be used in the ELISA. The ELISA
method was a modified version of that described by Engvall and Perlman (9). Flat-bottomed
polystyrene microtest plates (Dynatech Laboratories, Inc., Alexandria, VA) were preincubated
for 30 min at 37'C in a humidified chamber to minimize the electrostatic activity of the
solid phase. The wells of each plate were then coated with 100 gl of purified goat anti-PT
Igs (prepared at Sclavo Research Center, Siena, Italy) and diluted 1:2,000 in PBS. Plates were
incubated for 3 h at 37°C. After incubation, the wells were washed with 150 ul of 0.15 M
PBS containing 0.05% Tween and 0.02 % sodium azide (PTA), and then 6 ng ofPT (affinity
purified on a fetuin column as described by Sekura [10]), in 100 gl of0.05 M carbonate buffer
(pH 9.6) was added to each well. Plates were incubated overnight at room temperature in
a humidified chamber. The coating buffer was aspirated, and wells were washed with 150
ul of PTA. To minimize nonspecific adsorption of serum proteins to the plastic, wells were
coated with 150 wl of a blocking solution consisting of 21 70 BSA in PBS, and then incubated
for 2 h at 37°C. Plates were then washed three times in PTA and 100 g1 of fourfold diluted
test serum (1:20-1 :1,280 dilution) and eight twofold serial dilutions of reference serum
(1:20-1:1,280 dilution) in 0.15 M PBS containing 0.1% BSA and 0.2% sodium azide (PBS-
BSA) were added to the wells. The U. S. Reference Pertussis Antiserum (human) containing
200 U/ml ofIgG anti-PT was kindly provided by the Center for Drugs and Biologics, Bethesda,
MD. After incubation for 1.5 h at 37'C, plates were washed three times with PTA and 100
g1 ofp-nitrophenyl phosphate substrate (Sigma Chemical Co., St. Louis, MO). 1 mg/ml in
1 M diethanolamine, pH 9.8, containing 1 MM MgC12, was added to each well. The
enzyme-substrate reaction, which developed at room temperature, was stopped after 30 min,
and the OD of the samples was measured at 405 nm against a blank (substrate in diethanola-
mine, pH 9.8) on a Titertek Multiskan (Flow Laboratories, Inc., McLean, VA). Controls
for each plate included wells with serum samples but no antigen. Each serum sample was
tested in duplicate, and absorbance values were averaged. The calculation of the ELISA anti-
body units in the test samples was determined in relation to the U. S. Reference Pertussis
Antiserum (11).
Antigens.
￿
Virulent (phase I) and nonvirulent (phase III) B. pertussis, B. parapertussis, and
B. bronchiseptica strains were used together with transposon-induced or deletion B. pertussis
mutants lacking one or more virulence-associated antigens (see Table I and Fig. 1 for sum-
mary). Bordetella strains were grown on Bordet-Gengou agar at 35'C for 72 h and Salmonella
typhi on LB agar at 37°C overnight. For inactivation, bacteria were harvested from plates,
washed in PBS, and resuspended in a 0.5% formalin solution in PBS and left overnight on
a mixer (Coulter Electronics Ltd., Luton, UK). After extensive washing, bacteria were
resuspended in PBS and stored at 4°C . The OD525 of the suspensions was determined, and
the number of cells per milliliter was calculated on previously established standard curves.
Production of hemolysis on BG agar and/or toxic effect on CHO cells (12) were adopted
as parameters for the control of phase I Bordetella species.
Soluble PT was purified from B. pertussis phase I culture supernatant as described by Sekura
(10), precipitated in ammonium sulfate, and kept at 4°C. Before use, it was resuspended
in PBS and heat inactivated (at 100°C for 45 min).
The 69-kD protein, purified from B. Pertussis outer membrane as previously described (13),
was kindly provided by Dr. Novotny (The Wellcome Research Laboratories, Beckenham, UK).
Mediafor CellStimulation and Growth.
￿
The culture medium was RPMI 1640 (Gibco Labora-
tories, Paisley, Scotland) supplemented with Lglutamine (2 mM), 1% nonessential amino
acids, 1% sodium pyruvate, 50 wg/ml gentamycin, 5 x 10-5 M 2-ME, and 10% heat-inacti-
vated pooled human AB serum (RPMI-HS) or FCS (RPMI-FCS). To support the antigen-
independent growth of T cell clones, RPMI-HS was supplemented with 50 U/ml human
rIL-2 (Hoffman-La Roche, Inc., Nutley, NJ).
Proliferation Assays.
￿
Fycoll-Hypaque (Pharmacia Fine Chemicals AB, Uppsala, Sweden)
-separated PBMC were incubated (105 cells/well in RPMI-HS) for 6 d with different antigen
concentrations in 96-well flat-bottomed Cluster 96 plates (Costar, Cambridge, MA). When
antigen-stimulated T lymphocyte clones were tested, they were incubated at 2 x 104 cells/well
for 3 d in the presence of 2 x 104 mitomycin C-treated EBVtransformed autologous B lym-
phocytes (EBVB cells) and antigens in RPMI-FCS (14). All assay cultures were pulsed forBacterium
B . pertussis Tohama (BP)
B . parapertussis 3715 (BPP)
B . bronchiseptica CCUG 7865 (BB)
B . bronchiseptica 7866
B . bronchiseptica ATCC 4617
B . pertussis Tn5-induced mutants (18) :
Strains :
BP 353
BP 356
BP 348
BP 347
B . pertussis FHA deletion mutant"
Strains :
BP 536 fha 101
BP 536 fha 102
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TABLE I
Bacteria Used as Antigens in Proliferation Assays
Properties
Virulent (phase I)
Virulent (phase I)
Virulent (phase I)
Nonvirulent (phase III) variant of
7865 obtained at Sclavo
Nonvirulent (phase III)
Phenotype :
reduced production of filamentous
hemagglutinin (FHA- )
PT subunit 3 deficient (S3- )
adenylate cyclase and hemolysin
deficient (AC- , HLY-)
air-regulated proteins deficient
(vii), equivalent to phase III
Genotype :
2.4 kb in frame deletion (Fig . 1,
￿
)
in FHA structural gene (AaB)
3 .4 kb deletion (Fig. 1, -~-) in fhaB
with the 3' region out of frame
(Fig .
￿
1 ; ---)
BP, B . pertussis .
" David Reiman, Stanford University, Stanford, CA, personal communication .
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FIGURE 1 .
￿
B . pertussisFHA de-
letion mutant .
the last 16-18 h with 1 gCi of [3H]thymidine (sp act, 185 GBq/mmol; Amersham Interna-
tional, Amersham,UK). Cellswere then harvested on glass-fiber filters with a cell harvester
(Skatron, Lier, Norway), and incorporated radioactivitywas determined by liquid scintilla-
tion counting.
Cloning ofB . peerttussis-speck TLymphocytes.
￿
PBMC isolated from heparinized bloodofdonor
R.R. by Ficoll-Hypaque were cultured in flat-bottomed Cluster 96 plates at the concentra-
tion of 105/well in 0.2 ml RPMI-HS in the presence of 106 B, pertussis cells. This antigen con-
centration was found to induce a strong proliferation response by PBMC from this donor .
After 7 d, the activated T cells were expanded in medium supplemented with rIL-2, and
after another 7 d, lymphoblasts were cloned by limiting dilution (14). Cells were seeded at
0.3 per well in Terasaki trays in the presence of 105 allogeneic mitomycin C-treated PBMC,
in RPMI-HScontainingPHA (1 Itg/ml) and IL-2 . About 50% ofthe clones obtained proved
antigen specificwhen tested in proliferation assays againstB . pertussis. These clones were main-
tained in culture by periodic restimulation in thepresence ofallogeneic mitomycinC-treated
PBMC, PHA, and rIL-2 . T lymphocyte clones were analyzed for cell surface phenotypeby
direct immunofluorescence on a FRCS (FACStar, Becton Dickinson & Co., Erembodegem,1354
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Belgium). Both phycoerythrin- and fluorescein-conjugated OKT3, OKT4, and OKT8 mAbs
(Ortho Diagnostic Systems, Inc., Raritan, NJ) were used.
Immortalization ofBLymphocytes with EBV .
￿
PBMC from donor R.R. were transformed with
EBV as described (15). Briefly, 107 PBMC were resuspended in 10 ml RPMI-FCS containing
30% supernatant of the EBVproducing marmoset cell line B95.8 and 600 ng/ml cyclo-
sporin A (Sandoz, Basel, Switzerland) and were distributed in a flat-bottomed 96-well plate
at 5 x 104/well.
StatisticalAnalysis.
￿
The calculation of the ELISA antibody units was based on the parallel
line bioassay procedure described by Brownlee (16) using an ELISA unitage calculation pro-
gram distributed by the Laboratory of Pertussis, Center for Drugs and Biologics, Bethesda,
MD. An increase in ELISA units of more than mean negative controls plus 3 SD was ar-
bitrarily considered as a significant level of anti-PT antibodies.
Results of proliferation assays are presented as the mean cpm of triplicate cultures ± SD.
Statistical significance was calculated by student's t test.
Results
Identification ofImmune Donors Against B. pertussis.
￿
Although no specific serological
or cellular tests have been established for the direct measurement of host immunity
to pertussis infection, donors with positive and negative anamnesis for whooping
cough in childhood were screened for antibody titers against PT by ELISA, and
for their proliferative response to B. pertussis. The aim was to identify donors suitable
for the generation of T cell clones specific for B. pertussis antigens. As shown in Fig.
2, all donors with negative anamnesis had very low levels of anti-PT antibodies, when
compared with a standard positive reference serum (see reference 11 and Materials
and Methods). On the other hand, the levels of anti-PT antibodies in the group
with positive anamnesis varied from 0 to 130 U/ml. This clearly indicates that anti-
PT antibodies can be found only in a proportion of adults affected by pertussis in
childhood (27.7%), considering as a significant increase in antibody values those
higher than the mean of the group with negative anamnesis, plus 3 SD.
Mononuclear cells from peripheral blood of 9 out of 36 positive donors and of
5 out of 16 negative donors were tested for proliferation in response to inactivated
whole B. pertussis. As shownin Fig. 3, a significant proliferation in a dose-dependent
fashion was observed in the majority of donors with positive anamnesis; however,
some of the negative donors also showed a low, but consistent increase in prolifera-
tion in response to B. pertussis antigens. The ELISA units and the maximal prolifera-
tion for all the donors tested are reported in Table II, which shows that in -50%
of the positive donors, these two parameters correlate, but this is not a general fea-
ture. Therefore, theseresults further confirm the difficulties in identifying immuno-
logical tests predictive of the host response against Bordetella infections.
Generation of TCell Clones Against WholeInactivatedB. pertussis Bacteria.
￿
On the basis
of these results, a donor with positive anamnesis and high ELISA titers as well as
proliferative responses was chosen for the generation ofT cell clones. Thus, PBMC
from donor R.R . were stimulated in vitro for 7 d with formalin-killed B . pertussis
phase I. The antigen-stimulated cellswere then expanded in rIL-2-containing medium
and cloned in the presence of PHA and nonautologous feeder cells (14). Specific
clones were identified by means of proliferation in response to killed B. pertussis as
shown in Fig. 4. A total of 12 B. pertussis-specific clones were obtained. Their pheno-
type was observed to be CD4+8- , and clones were MHC class 11 restricted, asE
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FIGURE 2. Antibody levels against PT in serum from
normal adults with positive and negative anamnesis for
whooping cough during childhood. Shaded area represents
mean of negative controls t 3 SD.
demonstrated byinhibition ofantigen-induced proliferation byanti-HLA-DRmAbs
(data not shown).
Recognition ofAntigensfrom Whole Inactivated Bacteria by T Cell Clones.
￿
To analyze
further the fine specificity of the anti-B. pertussis clones, a panel of Bordetella wild-
type strains, as well as mutants, was used as antigen in proliferation tests together
with a negative control such as Salmonella typhi (Table I). A representative experi-
ment with four different T cell clones is shown in Fig. 5. As expected, the prolifera-
tive response ofthe differentclones varied according to the panel ofbacterial species
used as antigens. A summary of 30 experiments performed is shown in Table III
with a tentative prediction ofthe antigen recognized. On the basis ofthe reactivity
patterns ofthe clones against Bordetella species and mutants, it can be suggested that
clone 6 may recognize FHA. In fact, this clone proliferated in response to phase
I Bordetella species, but did not recognize the FHA low producer B. pertussis 353 (7)
and the phase III B. bronchiseptica and B. pertussis 347, both totally lacking FHA.
Clones 23 and32 recognizeB. pertussis-specific antigens, sincetheydidnotproliferate
in responseto B. pertussisand B. bronchiseptica. Furthermore, the negative results with
phase III B. bronchiseptica and B. pertussis 347 suggest that the antigen(s) recognized
is virulence associated. Clones 7, 8, 31, and 34 recognize virulence-associated Bor-
detella antigens, since they failed to proliferate in response to phase III B. bronchisep-
tica andB. pertwsis347. Finally, clones 9, 17, 26, 28, and 30 recognize nonvirulence-
FIGURE 3.
￿
Proliferation of PBMC in re-
sponse to inactivated B. pertussisfrom normal
adults with positive (A) or negative (B)
anamnesisforwhooping cough. Background
proliferation ranged from 0.3 to 0.6 cpm x
10-3 in all donors.1356
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associated Bordetella antigens, since they proliferated in response to all the Bordetella
species, regardlessoftheir virulenceand antigenicdeficiencies. All the clones tested
are specific for Bordetella species since they did not recognize inactivated S. typhi.
Since clone 6 was likely to recognize FHA, the analysis ofits fine specificity was
further extendedusingtwonew Bordetella mutantswithdefined deletionsin the struc-
tural gene for FHA (see Table I). As shown in Table IV, clone 6 is capable ofrecog-
nizing B. pertussis FHA 101, but not FHA 102. This would indicate that the deter-
minant recognized byclone 6 is likely to be coded for by the sequence downstream
from the second Barn HI site on theFHA structural gene, which representsapproxi-
mately the COOH-terminal halfofthe protein. This part is missing in the mutant
FHA 102.
RecognitionofSolubleBacterialAntigens by TCell Clones.
￿
Theclusters ofclones against
B . pertussis-specific antigens (cluster 2) and virulence-associated Bordetella antigens
(cluster 3) were then tested against soluble antigens such as PT, which is present
only on B . pertussis, and the 69-kD outer membrane protein, which is present on
i C
X
v
4
' The background proliferation of cells without antigen was subtracted.
1 Indicates correspondence between antibody levels and cellular response.
TABLE II
Humoral and Cellular Immunity to B. pertussis Antigens in Adults
with Positive and Negative Anamnesis for Whooping Cough
4 RR6
f RR8
-M RR9
ir RR17
i RR22
FIGURE 4.
￿
Proliferative response of T cell clones in response to
inactivated B. pertussis.
Positive
ELISA
U/ml
donors
Max cpm
(x 10-3)'
Negative
ELISA
U/ml
donors
Max cpm
(x 10-1)
M.M .1 130 37 G.S.1 4 6
E.B.1 66 24 D.A. 2 11
R.R.1 53 29 D.R.1 1 7
F. P.1 32 11 G.R.1 3 4
A.T. 20 25 M.P. 7 11
P.B . 6 36
S . N. 6 38
M.R. 3 28
G.G. 3 21Bacteria x 10-6/well
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FIGURE 5. Proliferative re-
sponse of T cell clones in re-
sponse to inactivated Bordetella
species and mutants.
all the three virulent Bordetella species, although with slightly different molecular
weights (13). It was found that clones 23 and 32 from cluster 2 do not proliferate
in response to inactivated PT, whereas clones 7, 31, and 34 from cluster 3 were able
to recognize the 69-kD protein (Table V). However, clone 8 from cluster 3 did not
proliferate in the presence ofthe69-kD protein. Thus, this result would suggest that
clone 8 may differ from theotherclones of cluster 3. Its specificity would be directed
against an additional virulence-associated, still unknown, Bordetella determinant.
T Cell Clones Against PT .
￿
Based on the experiments with Bordetella wild species
and mutants and on those with soluble bacterial antigens, it can be concluded that
none of the T cell clones obtained are against PT. To verify whether this was due
to a low frequency or a total lack of such memory T lymphocytes or rather to a
deficiency in antigen presentation when whole bacteria were used to stimulate im-
mune PBMC, anew generation of T cell clones from the same R.R. donorwasob-
tained by stimulating his PBMC in vitro with inactivated PT. Table VI shows that,
indeed, Tcell clones can be obtained against PT. Therefore, a T cell memory exists
against PT, but it cannot be evoked by whole bacteria used as antigen.
Discussion
Theextraordinary developments in protein chemistryand molecularbiologyhave
offered new possibilities in producing safe and effective vaccines. Important results
have been obtained regarding methods for development of newvaccines for human
andanimal diseases, andarecombinant vaccine againsthepatitisB is alreadyin use.
Amongthe priority targetsindicatedby the World Health Organization to obtain
safe and effectivevaccines, one ofparticular interest forboth developedanddeveloping
countries, is the prevention of pertussis. In fact, this diseasehadalreadybeen efficiently
reduced by the cellular vaccine consisting of inactivated B. pertussis bacteria; how-
ever, due to its side effects, this vaccine was withdrawn in many countries, resulting
in the return of a significant mortality from whooping cough even in highly devel-
oped countries (3). Therefore, pertussis represents on the one hand an interesting
experimental system, sinceit is alreadyknown that it is possible to actively immunize
against the disease and give protection; furthermore, it is also extremely important
to obtain asafe vaccine with high compliance to continue thevaccinationcampaign.
However, the identification ofthe simplest immunogenic structures capable of con-
ferringaprotective immunity is noteasy, due to the complexity of thebacterialstruc-1358
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￿
Proliferative response
None
￿
4.5 t 0.9'
B. pertussis
￿
11 .8 ± 1 .71
B. parapertussis
￿
7.4 t 0.11
B. bronchiseptica (phase III)
￿
3.5 t 0.3
BP 353
￿
3.7 t 0.5
BP 347
￿
3.6 t 0.2
B. pertussis "FHA 101"
￿
22.6 t 2 .51
B. pertussis "FHA 102"
￿
3.9 t 0.3
BP, B. pertussis.
' Mean cpm (x 10-3) ± SD of triplicate cultures.
1 p < 0.01 vs. control.
tures. In the last few years, the genes of some among the most important proteins
ofB. pertussis have been cloned (5-8) and recombinant proteins are now becoming
available. Our study was begun with the goal of providing useful tools to identify
on a rational basis the immunogenic structures of B. pertussu proteins that might
form a new synthetic and/or recombinant vaccine against pertussis.
Afirst problem that we tried to solve was the immunological characterization of
adults who experienced whooping cough during childhood. As also observed by others,
wefound that thehumoral response against PTseldom correlates with theanamnesis
for pertussis. More interestingly, the majority of donors with positive anamnesis
showed a significant in vitro proliferation against killed B. pertussis bacteria. This
parameter was higher in donors with positive anamnesis compared with those with
anegative one. However, thislast group also showed someproliferation in response
to bacterial antigens. This might be due to known crossreactivities between B. per-
tussis and other Bordetella species such as B. bronchiseptica and B. parapertussis, and/or
crossreactivitieswith other bacteria (17). It is howeverofinterest that acell-mediated
TABLE V
Specificity ofAnti-B. Pertussis Human T Cell Clones Against PT and
69-kD Outer Membrane Protein
DE MAGISTRIS ET AL.
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TABLE IV
Proliferation of the FHA-reactive Clone RR6
' Mean cpm (x 10-3) ± SD of triplicate cultures.
1 p < 0.01 vs. control.
5 p < 0.05 vs. control.
Exp. Cluster Clone None
Antigen
PT
B. pertussis (1 Wg/ml)
6.9 x 104 MW
(10 Rg/ml)
1 2 RR 23 4.0 ± 0.2' 17.5 ± 0.41 3.7 ± 0.1 ND
2 RR 32 4.4 ± 0.6 28 .7 ± 4.35 4.2 t 0.4 ND
2 3 RR 7 2.8 1 0.1 10.1 ± 0.71 ND 17.6 ± 0.11
3 RR 31 3.1 ± 0.6 16.0 t 0.51 ND 20.2 t 4.55
3 RR 34 2.5 t 0.1 8 .1 ± 1 .21 ND 11 .1 ± 1 .81
3 3 RR 8 0.8 ± 0.3 6.2 ± 0.81 ND 0.8 ± 0.11360
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TABLE VI
Response of Human T Cell Clones to Purled PT
' Mean cpm (x 10-s) t SD of triplicate cultures.
1 p < 0.01 vs. control.
§ p < 0.05 vs. control.
response such as specific lymphocyte proliferation seems to better correlate with an
anamnesis for pertussis and further studies on this aspect are in progress.
These preliminary experiments onthe characterizationofimmune responsesagainst
B. pertussis antigens formed the basis for the identification of an immune donor in
orderto increase the probabilityofobtainingT cellclones against pertussisantigens.
Thus, donor R.R. was chosen, and his peripheral blood was used to obtain a first
generationofTcell clones directed againstBordetellaantigens. To analyze thespecificity
ofthese clones, it was decided first to stimulate them with a panel of Bordetella wild-
type strains and mutants deficient for some antigens (18). This approach resulted
in clustering the 12 clones obtained in four different groups, which recognized (1)
FHA; (2) B . pertussis-specific antigen(s); (3) virulence-associated Bordetella antigen(s);
and(4) nonvirulence-associated Bordetellaantigens. The prediction that cluster 1 recog-
nizes FHA was furtherconfirmed byusingtwo newB. pertussismutants(D. Relman,
unpublishedresults) that allowed the clone's specificity tobedefined forthe COOH-
terminal portion ofthe FHA protein. Interestingly, the antigen recognized by three
clones ofcluster 3 was also positively identified as the 69-kD outer membrane pro-
tein described by Novotny et al. (13), while the specificity ofthe fourth clone seems
to be directed to a virulence factor different from the 69-kD protein. In addition,
the possibilitythat cluster 2 recognizes PT, suggested bythe experimentswith whole
inactivated bacteria, was disproved by using soluble PT as antigen. Since cluster
4 recognizes nonvirulence-associated Bordetella antigens, one could conclude that PT
is not the most immunogenic structure of inactivated whole B. pertussis recognized
in vitro by memory T cells from a donor who had whooping cough during child-
hood. However, in a new series ofexperiments, it waspossible to obtain Tcell clones
from donor R.R. against PT by stimulating his PBMC in vitro with soluble PT.
This result would suggest that the diseasemay becapable ofgenerating immunolog-
ical memory against a variety ofB. pertussis antigens, including PT. The extrapola-
tion ofour in vitro result toan invivo vaccination withwhole inactivatedB. pertussis
might suggest that the protective immunity generated by the vaccine may not be
Clone None
Antigen
PT
RR-T106 2.9 t 0.3' 5 .1 ± 0 .81
RR-T207 2.3 t 0.4 7 .7 ± 1 .65
RR-T209 2.4 ± 0.5 5 .8 t 0.71
RR-T215 2.3 f 0.2 55.8 ± 2 .91
RR-T216 2.3 t 0.3 5.8 ± 0.91
RR-T218 2.1 ± 0.2 11 .3 t 0.71
RR-T219 2.6 f 0.2 9.9 ± 2 .0
RR-T220 1 .2 t 0.1 14.2 f 2 .11
RR-T226 2.4 t 0.2 57.3 ± 3 .01
RR-T227 2.8 ± 0.2 12.0 ± 2.74
RR-T229 2.5 ± 0.0 32.6 ± 2.01directed againstPT, but rather againstotherbacterial antigens. Thus, antigens such
as FHA and the 69-kD protein may be sufficient to induce protection against the
diseaseifused in an acellularvaccine. However, this conclusion doesnot imply that
a vaccine composed of only PT would not be efficient. Indeed, this has been the
case when tested in an animal model (19), which is considered rather artificial but
also predictive for vaccine effectiveness.
The approach of generating T cell clones against B . pertussis antigens from im-
mune donors can thereforebe considered auseful tool forthe developmentofa safer
and more effective vaccine against whooping cough.
Summary
To identify the minimal structures that may be important for the creation of a
synthetic and/or recombinant vaccine against whooping cough, humanT cell clones
were obtained against Bordetella antigens. Cloned peripheral blood T lymphocytes
from an immune donorwere grown in IL-2 and tested for proliferation in response
to inactivated Bordetella species(B. pertussis, B . parapertussis, and B . bronchiseptica) and
mutants deficient for the expression ofvirulence-associated antigens. All the T cell
clones obtained were CD4'8- and recognized specifically the Bordetella antigens
when presented byautologous B cells. Onthe basis oftheresponsiveness tothe whole
inactivatedbacteria, itwas possibleto cluster the 12 clones obtained intofour groups
with thefollowing specificity: (1) filamentous hemagglutinin (FHA); (2) B . pertussis-
specific antigens; (3) virulence-associated Bordetella-specific antigens; and (4)
nonvirulence-associated Bordetella-specific antigens. Using two newB. pertussis dele-
tionmutants, clone6(representative ofcluster 1) was found torecognize the COOH
terminus ofFHA. Furthermore, three out offour clones ofcluster 3were specifically
stimulated by the soluble 69-kD protein from the outer membrane of B. pertussu .
Surprisingly, none ofthe twelve clones obtained by stimulation in vitro with whole
inactivatedbacteria recognized pertussis toxin (PT), which is believed tobe themost
important proteinto be included in anacellular vaccine. However, when anewgener-
ation ofclones was obtained using soluble PT as the in vitro stimulus, it was ob-
served that 11 clones ofthis group recognized this antigen. Thus, PT does not seem
to be the most representative antigen on the whole inactivated bacteria, although
T cell memory against PT exists in a donor who had the disease several years ago.
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